GoodRX | GDRX | Long at $5.00

GoodRX GDRX . Going long at $5.00.

Pros:

• Revenue is growing and is expected to reach almost $1 billion by 2027
  
• Debt-to-equity = 0.71x (low)
  
• Monthly active users continue to increase (+7% during Q3 of 2024)
  
• From a technical analysis perspective, the downward trend is starting to reverse, and the price has connected with my historical simple moving average (likely leading to a price increase)
  

Cons:

• Not yet profitable
  
• A lot of market competition
  
• Insiders exercising of options outweighs awarding of options
  
• No dividend
  

Targets:

1. $6.00
   
2. $7.00
   
3. $8.00
   
4. Substantially higher if partnerships emerge and profitability begins